<DOC>
	<DOCNO>NCT00744081</DOCNO>
	<brief_summary>The purpose study show superiority complete response combination therapy MTC plus Glivec patient refractory relapse AML compare historical control treat MTC alone .</brief_summary>
	<brief_title>Imatinib + MTC Relapsed / Refractory Acute Myeloid Leukemia ( AML )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>Refractory AML primary therapy First relapse safe previous diagnosis de novo secondary AML Age &gt; 18 year Serum bilirubin &lt; 2.0 mg/dl Serum creatinine &lt; 1.5 time normal value creatinine clearance &gt; 60 ml/min ECG heart echography prior start therapy without severe finding Overall condition &lt; 2 accord ECOG criterion Life expectancy &gt; 6 week Written inform consent patient full legal capacity Serious secondary disease ( clinically relevant cardiac disease , chronic obstructive pulmonary disease , hepatic dysfunction , renal insufficiency ) Active secondary neoplasia ( exception : adequately treat basalioma epidermoid cancer cervical carcinoma ) Known hypersensitivity topoisomeraseI inhibitor Overall condition &gt; 2 accord ECOG criterion Pregnant/breast feed woman Serious intercurrent infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
</DOC>